6[1]Pitt B.ACE inhibitor co-therapy in patients with heart failure:rationale for the Randomized Aldactone Evaluation Study (RALES).Eur Heart J,1995,16(Suppl N):S107-S110.
7[2]Structhers AD.Aldosterone escape during ACE inhibitor therapy in chronic heart failure.Eur Heart J,1995,16 (Suppl N):S103-S106.
8[3]Zannad F,Dousset B,Alia F.Treatment of congestive heart failure:interfering the aldosterone-cardiac extracellular matrix relationship.Hypertension,2001,38:1227-1232.
9[4]Zannad F,Alia F,Dousset B,et al.Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure.Circulation,2000,102:2700-2706.
10[1]Chobanian AV,Bakris GL,Black HR,et al.The seventh report of The joint national committee on prevention,detection,detection,evaluation,and treatment of high blood pressure:the JNC 7 report.JAMA,2003,289:2560-2572.
